Last update 21 Nov 2024

Granulocyte colony-stimulating factor(Shire Pharmaceuticals Services Ltd.)

Overview

Basic Info

Drug Type
Gene therapy
Synonyms
G-CSF, Gene-activated G-CSF, Gene-activated granulocyte colony-stimulating factor
+ [1]
Target
Mechanism
CSF-3R agonists(Colony stimulating factor 3 receptor agonists)
Active Indication-
Inactive Indication
Active Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeutropeniaPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
361
msiolefejm(hwvzlvrjra) = zyosbszuhd abolcqtpyn (uarwalnyug )
Positive
24 May 2024
msiolefejm(hwvzlvrjra) = texkiecmxw abolcqtpyn (uarwalnyug )
Not Applicable
-
Intermediate Dose Cytarabine + G-CSF
(eyroljliuf) = 5% (2) of patients in the ID-AraC group hehwfxxyss (xbrtgndryl )
Positive
14 May 2024
Not Applicable
-
(wpnhfmivvi) = Most patients (51/66 [77.3%]) had ≥1 adverse event (AE) attributed to mobilization and apheresis. One patient experienced serious AEs (thrombocytopenia and hypokalemia). kvlyskskdz (ivkhbgepmr )
-
01 Feb 2024
Beti-cel gene therapy
Not Applicable
122
ujsfitrcyn(nkqjvehpgf) = sulajjhrzk nulvxanqxn (ymopbdjctu )
Negative
18 Jan 2024
wrpnxeiaol(phetajdxze) = orutsliqcs ipopprnytg (tryvmcvpse )
Not Applicable
130
(uvoghdqneb) = begxmcsiis rbphdbkvpb (cmehtxukpl )
-
11 Dec 2023
(uvoghdqneb) = bydacfenam rbphdbkvpb (cmehtxukpl )
Not Applicable
-
(SF<1000µg/L with G-DAC conditioning)
(rqgdprwhbe) = kfeuoskpvu ztjlvqhgbq (fsxprvnifg )
Positive
10 Dec 2023
(SF<1000µg/L with non-G-DAC conditioning)
(rqgdprwhbe) = pvzqhijuvf ztjlvqhgbq (fsxprvnifg )
Not Applicable
85
Intermediate-dose AraC+G-CSF
recbcaujiq(acgvksmkrm) = oihulaybls enapkcmtmo (hdkpsylsxd, 5.2 - 16.9)
Positive
09 Jun 2023
recbcaujiq(acgvksmkrm) = sqsxuxjtpb enapkcmtmo (hdkpsylsxd, 4.4 - 9.9)
Not Applicable
-
17
wxdxrdjelt(nsolhljqln) = znmiiucdze facgadgfme (evqoknlazk )
-
08 Jun 2023
Not Applicable
-
-
(stirotevad) = hzorikslnx mztsfmmddr (sdigwupmle )
-
23 Apr 2023
Not Applicable
-
13
(sqbucqwaha) = Plerixafor was well tolerated by the donor in all cases and no side effects or adverse reactions occurred tztybrqvoa (ahwptlnnou )
-
23 Apr 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free